Iv Zoledronic acid use in very elderly :balancing fall related fracture prevention and frailty

Introduction: Very elderly individuals are at very high risk of falls and fragility fractures and treatment decisions are often complicated by frailty , multimorbidity and limited life expectancy.  Intravenous Zoledronic acid offers effective fracture prevention with ones yearly dosing but safety and benefit in very frail older adults remains uncertain.

Objectives: To evaluate the safety and clinical outcomes of iv Zoledronic acid in very elderly patients with corelation with baseline frailty status.

Methods: A retrospective observational analysis was conducted in patients aged 85 year and above receiving iv Zoledronic acid .Frailty was determined using clinical indicators including functional dependence , mobility impairment , cognitive impairment and comorbidity burden . Outcomes assessed were mortality , timing of death following the infusion and treatment related adverse events.

Results : Forty patients were analysed. Two patients died after receiving the first dose of iv Zoledronic acid : one patient after five months and the other after 12 months. Both individuals were classified as severely frail at baseline , with advanced multimorbidity and functional dependence. Neither death was temporarily related to the infusion nor attributed to the iv Zoledronic acid.

No serious acute infusion related adverse events were recorded. Mild, self limiting acute phase reactions occurred infrequently . Renal function and calcium levels remained relatively stable in non frail and moderately frail patients. 

Treatment tolerance and follow up completion were poorer among severely frail individuals.

Conclusions: In this real world cohort of very elderly patients outcomes following Iv Zoledronic acid were more closely associated with baseline frailty than with treatment related toxicity. Severely frail patients demonstrated higher mortality during follow up reflecting competing health risks. incorporating frailty assessment in osteoporosis management may help identify patients most likely to benefit from iv Zoledronic acid while avoiding treatment in those likely to gain meaningful fracture prevention benefit.